Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Global experts in antibody-drug conjugate (ADC) development, oncology clinical development and early-phase trial design, appointed to support advancement of Byondis’ differentiated ADC pipeline and a...
-
Global experts in antibody-drug conjugate (ADC) development, oncology clinical development and early-phase trial design, appointed to support advancement of Byondis’ differentiated ADC pipeline and a...
-
Tacalyx Secures €11 Million to Advance Lead TACA-Targeting ADC Programme Toward the Clinic Berlin, Germany, April 29, 2026 (GLOBE NEWSWIRE) -- Tacalyx, a leader in the discovery and development of...
-
Presentations highlight therapy-induced senescence as a new opportunity and reinforce STX-1’s potential as a differentiated approach in solid tumors.
-
SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,...
-
VERAXA shareholders approve merger & issuance of new shares to Voyager. Both resolutions are prerequisites for the closing of the business combination.
-
“Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences" Featuring Serina Therapeutics’ CEO - Wednesday, February 4, 2026 Hear how FDA initiatives in 2026 may impact...
-
DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies
DISCO signs exclusive deal with Amgen to develop cancer therapies from its surfaceome platform; deal worth up to $618M plus royalties.
-
Hummingbird Bioscience today announced that the first patient has been dosed in a Phase I clinical trial of HMBD-501.
-
DISCO Pharmaceuticals appoints biotech leader Mark Manfredi as CEO and raises €36M to advance surfaceome-targeted ADC therapies for hard-to-treat tumors